News

News-Medical.Net on MSN8h
What’s behind Gen Z’s skepticism about Ozempic and Wegovy
A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...
Novo Nordisk’s stellar Wegovy-fuelled run of hiking sales guidance could be ending
But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...
Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Street's Pessimism
Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...
Zacks Investment Research on MSN18h
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...
US judge denies injunction, restricts copies of weight-loss drug Ozempic
A US judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and ...
'I'm a doctor - here's why some people are more at risk of hair loss on weight loss jabs than others'
A doctor has shared some of the common reasons people taking weight loss jabs may notice hair loss, including those most likely to experience the side effect and how to combat it ...
Ozempic copies restricted after US judge deni
April 24 - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge ...
Zacks.com on MSN18h
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.